Established in 1996 by academicians of the Chinese Academy of Engineering, Shanghai Shyndec Pharmaceutical Co Ltd (Shanghai Shyndec) is a high-tech pharmaceutical enterprise engaged in the R&D, production and sale of pharmaceutical products. The company was listed on the Shanghai Stock Exchange on June 16, 2004 (Stock code: 600420, abbreviated as “Shanghai Shyndec”). It was incorporated into China National Pharmaceutical Group Co Ltd (Sinopharm) in April 2010.

Following decisions and arrangements of the State-owned Assets Supervision and Administration Commission and its parent company, Sinopharm, the company engaged in the restructuring and integration of the chemical and pharmaceutical industry sector from 2016 to 2018. After the restructuring, Shanghai Shyndec was incorporated into Sinopharm under the chemical pharmaceutical sector with strengthened capability of resource allocation and a clearer focus on core business operations.

Shanghai Shyndec has 23 wholly-owned or partially-owned subsidiaries, including 13 second-tier enterprises and 10 third and fourth-tier enterprises, with nearly 12,000 employees in total. Its 15 production bases are distributed in 11 provinces and cities across the country. The company had 1,456 drug approvals and 19 veterinary vaccine approvals as of the end of 2021, with 29 series of products with annual sales exceeding 100 million yuan ($14.02 million) each, combined main business revenues exceeding 10 billion yuan and profits exceeding 1 billion yuan. With a consolidating market position, the company ranked 12th on the list of China’s top 100 chemical pharmaceutical companies in 2021.

Shanghai Shyndec adheres to the “one body, two wings” strategy with chemical pharmaceutical industry as the main body and biopharmaceutical and health business as the two wings. Committed to the corporate philosophy of “all for health, health for all”, it focuses on five major areas: anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism and endocrine and anesthetics and psychiatric drugs. It has optimized its industrial layout and achieved healthy and stable development through multiple driving forces to become an innovative-driven, leading pharmaceutical company in China and the world and an influential industry leader with vitality and strength.